metyrapone has been researched along with Panic Disorder in 3 studies
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Study participants included 14 patients with panic disorder (DSM-IV criteria) and 14 healthy control subjects who underwent a standard overnight metyrapone test and a combined metyrapone/low-dose dexamethasone test." | 9.11 | Metyrapone tests in patients with panic disorder. ( Alm, B; Kellner, M; Schick, M; Struttmann, T; Wiedemann, K; Yassouridis, A, 2004) |
| "Study participants included 14 patients with panic disorder (DSM-IV criteria) and 14 healthy control subjects who underwent a standard overnight metyrapone test and a combined metyrapone/low-dose dexamethasone test." | 5.11 | Metyrapone tests in patients with panic disorder. ( Alm, B; Kellner, M; Schick, M; Struttmann, T; Wiedemann, K; Yassouridis, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kellner, M | 2 |
| Schick, M | 2 |
| Yassouridis, A | 1 |
| Struttmann, T | 1 |
| Wiedemann, K | 2 |
| Alm, B | 1 |
| Belgorodsky, A | 1 |
| Knyazhansky, L | 1 |
| Loewenthal, U | 1 |
| Arbelle, J | 1 |
| Cohen, H | 1 |
| Benjamin, J | 1 |
3 trials available for metyrapone and Panic Disorder
| Article | Year |
|---|---|
Metyrapone tests in patients with panic disorder.
Topics: Adrenocorticotropic Hormone; Adult; Antimetabolites; Case-Control Studies; Cortodoxone; Dexamethason | 2004 |
Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder.
Topics: Administration, Inhalation; Adrenocorticotropic Hormone; Antimetabolites; Carbon Dioxide; Corticotro | 2005 |
Prodissociative effects of metyrapone.
Topics: Adult; Dissociative Disorders; Humans; Male; Metyrapone; Panic Disorder; Placebos; Single-Blind Meth | 2001 |